高分子物理与化学实验室将于7月15日上午10：00在3#101会议室召开高分子科学前沿讲座2019年第八期，本次由肖海华老师组邀请Prof. Jianqin Lu（The University of Arizona, USA）作报告，具体内容请您参见附件！欢迎各位老师到场参加！

While chemotherapy delivery by nanocarriers has modestly improved the survival
prospects of metastatic cancers, additional engagement of the immune response could
be game changing. We demonstrate a nano-enabled approach for inducing robust anticancer
immunity using immunogenic cell death (ICD) and interfering in the
immunosuppressive indoleamine 2,3-dioxygenase (IDO) pathway. This is accomplished
by conjugating the IDO inhibitor, indoximod (IND), to a phospholipid (PL) that allows
prodrug self-assembly into nanovesicles or to be enveloped onto mesoporous silica
nanoparticles (MSNP). The porous MSNP interior allows co-encapsulation of the ICDinducing
oxaliplatin (OX). The OX/IND-MSNP induces effective innate and adaptive antipancreas
cancer (PC) immunity in a vaccination approach, direct tumor injection or IV
biodistribution to a Kras-mutated orthotopic PC site. Significant tumor reduction or
eradication is achieved by recruiting cytotoxic T lymphocytes, concomitant with
downregulation of Foxp3+ Tregs. Additionally, IND-PL itself can also serve as a liposomal
carrier for delivering ICD-inducing doxorubicin (DOX), which enhanced anti-breast cancer
immunity as compared to Dox-NP®. Upon blocking PD-1 immune checkpoint, DOX/INDLiposome
eradicates lung metastases. All considered, an innovative nano-enabled
platform has been established to switch an immune deplete to an immune replete
tumor microenvironment via combing ICD and immune checkpoint inhibition.